Insiders Bullish on Certain Holdings of XBI

A look at the weighted underlying holdings of the SPDR S&P Biotech ETF (XBI) shows an impressive 13.1% of holdings on a weighted basis have experienced insider buying within the past six months.

START SLIDESHOW:
10 ETFs With Stocks That Insiders Are Buying »

Merrimack Pharmaceuticals Inc. ( MACK), which makes up 2.12% of the SPDR S&P Biotech ETF (XBI), has seen 7 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $21,666,015 worth of MACK, making it the #2 largest holding. The table below details the recent insider buying activity observed at MACK:

MACK — last trade: $8.10 — Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
11/29/2013 Michael E. Porter Director 75,000 $3.60 $270,185.00
11/29/2013 William M. McClements SVP of Corporate Operations 7,000 $3.61 $25,255.00
11/29/2013 Anthony J. Sinskey Director 3,800 $3.92 $14,877.00
12/03/2013 Michael E. Porter Director 75,000 $4.17 $312,907.50
12/02/2013 William M. McClements SVP of Corporate Operations 2,000 $4.06 $8,119.20
12/03/2013 Sarah E. Nash Director 47,500 $4.17 $198,306.00
12/04/2013 Robert J. Mulroy President and CEO 33,100 $4.42 $146,225.87
12/06/2013 James H. Quigley Director 39,000 $4.70 $183,257.10
12/10/2013 Michael E. Porter Director 18,000 $4.38 $78,840.00
12/12/2013 William M. McClements SVP of Corporate Operations 4,000 $4.26 $17,059.20
12/17/2013 Michael E. Porter Director 25,000 $4.75 $118,811.25
05/05/2014 Michael E. Porter Director 15,000 $6.41 $96,150.00
05/05/2014 Gary L. Crocker Director 10,000 $6.69 $66,900.00
05/05/2014 Robert J. Mulroy President and CEO 5,000 $6.31 $31,550.00
05/06/2014 Gary L. Crocker Director 17,500 $6.89 $120,575.00
05/05/2014 Michael E. Porter Director 5,000 $6.12 $30,600.00
05/07/2014 Gary L. Crocker Director 4,400 $6.77 $29,788.00
05/07/2014 Sarah E. Nash Director 15,000 $6.79 $101,850.00
05/08/2014 Michael E. Porter Director 10,000 $6.59 $65,900.00
05/13/2014 Anthony J. Sinskey Director 5,000 $6.74 $33,700.00
05/16/2014 Michael E. Porter Director 15,000 $6.49 $97,400.00
05/19/2014 Gary L. Crocker Director 9,400 $6.68 $62,802.00
05/19/2014 James H. Quigley Director 5,000 $6.58 $32,900.00
05/20/2014 Gary L. Crocker Director 4,000 $6.69 $26,760.00

And Repligen Corp. ( RGEN), the #5 largest holding among components of the SPDR S&P Biotech ETF (XBI), shows 2 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $18,712,800 worth of RGEN, which represents approximately 1.83% of the ETF's total assets at last check. The recent insider buying activity observed at RGEN is detailed in the table below:

RGEN — last trade: $19.37 — Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
04/15/2014 James R. Rusche Senior Vice President 25,000 $3.05 $76,250.00
04/15/2014 Daniel P. Witt Senior Vice President 10,000 $3.05 $30,500.00

More from Stocks

Danica Patrick's Final Race at 2018 Indianapolis 500: What She Thinks About Cars

Danica Patrick's Final Race at 2018 Indianapolis 500: What She Thinks About Cars

Why The FANG Stocks' Dominance May Not Be So Bad For The Market

Why The FANG Stocks' Dominance May Not Be So Bad For The Market

At End of May, Investors Signalling They May Stay Away

At End of May, Investors Signalling They May Stay Away

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever